anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Desmopressin
Trial phase: Not Applicable
ATC code: H01BA02
SMILES: N=C(N)NCCC[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSCCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O
Sex: All
Age groups: Older Adult
Healthy volunteers: No
Participants at risk: 153
Group description: An epidural steroid injection (ESI) is a combination of a corticosteroid with a local anesthetic pain relief medicine.

Epidural Steroid Injection: Injection of epidural steroids into the lumbar spine
Eligibility criteria:
Inclusion Criteria:

65 years or older and a Medicare beneficiary.
Patients experiencing neurogenic claudication symptoms for at least 3 months duration which has failed to respond or poorly responded to physical therapy, home exercise programs, and oral analgesics.

LSS with neurogenic claudication diagnosed via:

Symptomatic diagnosis and
Radiologic evidence of LSS with unilateral or bilateral ligamentum flavum >2.5mm confirmed by pre-op MRI or CT performed within 12 months of baseline visit.
Patients with comorbid conditions commonly associated with spinal stenosis, such as osteophytes, facet hypertrophy, minor spondylolisthesis, foraminal stenosis, and/or disk protrusion may be included unless the treating physician has determined that the condition is too advanced.
Available to complete 6 month and one year follow-up visits.

Exclusion Criteria:

ODI Score < 31 (0-100 ODI Scale).
NPRS Score < 5 (0-10 NPRS Scale).
Prior surgery at any treatment level.
History of recent spinal fractures with current related pain symptoms.
Patients with Grade III or higher spondylolisthesis.
Motor deficit or disabling back and/or leg pain from causes other than LSS neurogenic claudication (e.g., acute compression fracture, metabolic neuropathy, or vascular claudication symptoms, etc.).
Unable to walk ≥ 10 feet unaided before being limited by pain. In this context, 'unaided' means without the use of a cane, walker, railing, wall, another person or any other means of walking assistance.
Patients previously randomized and/or treated in this clinical study.
Patients that have previously received the MILD procedure.
ESI during eight weeks prior to study enrollment.
Epidural lipomatosis (if it is deemed to be a significant contributor of canal narrowing by the physician).
On (or pending) Workman's Compensation or known to be considering litigation associated with back pain.
Intervention: Eltrombopag
Trial phase: Phase 2
ATC code: B02BX05
SMILES: CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 7
Group description: AMG531: Subcutaneous, weekly injection
Eligibility criteria:
Inclusion Criteria:

Patient who is diagnosed as AA and refractory to immunosuppressive therapy
Platelet ≤ 30,000/μL

Exclusion Criteria:

Concurrent active infection not adequately responding to appropriate therapy
HIV positivity
Bone marrow reticulin grade of > 1
Clinically significant cardiac disease
Arterial or venous thrombosis within the last 1 year before enrollment
Other cause of thrombocytopenia
AA with hemolytic predominant paroxysmal nocturnal hemoglobinuria (PNH)
Uncontrolled diabetes
Receiving any agent used to treat AA, including antithymocyte globulin (ATG) or ATG + cyclosporine within 6 months before starting study treatment and/or cyclosporine or anabolic hormone within 6 weeks before starting the study treatment
History of PEG-rHuMGDF, recombinant human thrombopoietin, AMG531, and other thrombopoietin (TPO)-receptor agonist
Who plans to conduct hematopoietic stem cell transplantation within 1 year
Intervention: Eltrombopag
Trial phase: Phase 2
ATC code: B02BX05
SMILES: CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: AMG531: Subcutaneous, weekly injection
Eligibility criteria:
Inclusion Criteria:

Patient who is diagnosed as AA and refractory to immunosuppressive therapy
Platelet ≤ 30,000/μL

Exclusion Criteria:

Concurrent active infection not adequately responding to appropriate therapy
HIV positivity
Bone marrow reticulin grade of > 1
Clinically significant cardiac disease
Arterial or venous thrombosis within the last 1 year before enrollment
Other cause of thrombocytopenia
AA with hemolytic predominant paroxysmal nocturnal hemoglobinuria (PNH)
Uncontrolled diabetes
Receiving any agent used to treat AA, including antithymocyte globulin (ATG) or ATG + cyclosporine within 6 months before starting study treatment and/or cyclosporine or anabolic hormone within 6 weeks before starting the study treatment
History of PEG-rHuMGDF, recombinant human thrombopoietin, AMG531, and other thrombopoietin (TPO)-receptor agonist
Who plans to conduct hematopoietic stem cell transplantation within 1 year
Intervention: Oxymetazoline Hydrochloride
Trial phase: Phase 3
SMILES: Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1.Cl
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 440
Group description: Oxymetazoline HCL Cream 1.0% (AGN-199201) applied to the face once daily for 52 weeks.
Eligibility criteria:
Inclusion Criteria:

-Moderate to severe persistent facial erythema associated with rosacea.

Exclusion Criteria:

Current treatment with monoamine oxidase (MAO) inhibitors
Raynaud's syndrome, narrow angle glaucoma, orthostatic hypotension, scleroderma or Sjogren's syndrome.
Intervention: Kenalog
Trial phase: Phase 4
SMILES: CC1(C)OC2CC3C4CCC5=CC(=O)C=CC5(C)C4(F)C(O)CC3(C)C2(C(=O)CO)O1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 79
Group description: Cervical epidural steroid injection with Triamcinolone 80mg and 1 mL 1% lidocaine. Total volume is 2 cc.

No Catheter Delivery will be used to deliver the medication.

Triamcinolone 80mg: C7-T1 Cervical interlaminar epidural steroid injection with Triamcinolone 80mg and 1 mL 1% lidocaine. Total volume is 2 cc.
Eligibility criteria:
Inclusion Criteria:

All patients ages 18-75 with C2-6 unilateral radicular pain who are scheduled to undergo cervical epidural steroid injection treatment.
Pain lasting greater than 2 weeks.
Pain resistant to a trial of conservative therapy (i.e. oral steroids,nonsteroidal anti-inflammatory drugs, opioids, muscle relaxants, physical therapy or chiropractic care)

Exclusion Criteria:

Patient refusal.
Lack of consent.
Systemic infection or local infection over planned injection site in posterior cervical spine.
Bleeding disorder, current use of anticoagulants or anti-platelet medications.
Intrinsic spinal cord lesions in the cervical region.
History of central neurologic, cerebrovascular, demyelinating or muscular disease.
Concomitant use of oral or injected steroids.
Allergy to medications being used for injection procedures.
Inability to communicate with staff or to participate in follow up.
Pregnancy.
Inability to perform handgrip or arm strength testing.
Cognitive deficit or motor neuron disease.
Daily opiate use that preceded the onset of cervical radicular symptoms or daily opiate use exceeding 3 months prior to study inclusion
Intervention: Kenalog
Trial phase: Phase 4
SMILES: CC1(C)OC2CC3C4CCC5=CC(=O)C=CC5(C)C4(F)C(O)CC3(C)C2(C(=O)CO)O1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 79
Group description: Cervical epidural steroid injection with Triamcinolone 80mg and 1 mL 1% lidocaine. Total volume is 2 cc.

Catheter targeted delivery will be used to deliver the medication.

Triamcinolone 80mg: C7-T1 Cervical interlaminar epidural steroid injection with Triamcinolone 80mg and 1 mL 1% lidocaine. Total volume is 2 cc.
Eligibility criteria:
Inclusion Criteria:

All patients ages 18-75 with C2-6 unilateral radicular pain who are scheduled to undergo cervical epidural steroid injection treatment.
Pain lasting greater than 2 weeks.
Pain resistant to a trial of conservative therapy (i.e. oral steroids,nonsteroidal anti-inflammatory drugs, opioids, muscle relaxants, physical therapy or chiropractic care)

Exclusion Criteria:

Patient refusal.
Lack of consent.
Systemic infection or local infection over planned injection site in posterior cervical spine.
Bleeding disorder, current use of anticoagulants or anti-platelet medications.
Intrinsic spinal cord lesions in the cervical region.
History of central neurologic, cerebrovascular, demyelinating or muscular disease.
Concomitant use of oral or injected steroids.
Allergy to medications being used for injection procedures.
Inability to communicate with staff or to participate in follow up.
Pregnancy.
Inability to perform handgrip or arm strength testing.
Cognitive deficit or motor neuron disease.
Daily opiate use that preceded the onset of cervical radicular symptoms or daily opiate use exceeding 3 months prior to study inclusion
Intervention: Hydromorphone
Trial phase: Phase 2
ATC code: N02AA03 | N02AA53 | N02AG04
SMILES: [H][C@@]12CCC(=O)[C@]3([H])Oc4c(O)ccc5c4[C@]13CCN(C)[C@]2([H])C5
Sex: Female
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 40
Group description: 50mcg intrathecal hydromorphone added to 1.5 mg 0.75% bupivicaine for single shot spinal anesthesia in primary cesarean sections.
Eligibility criteria:
Inclusion Criteria:

Elective primary cesarean section
Females age 18-40

Exclusion Criteria:

Emergency cesarean section
Anesthetic other than spinal
History of chronic pain or pre-op opioid use
Allergy to morphine or hydromorphone
BMI>40
Intervention: Everolimus
Trial phase: Phase 4
ATC code: L01EG02 | L04AA18
SMILES: COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(OCCO)C(OC)C2)CC(=O)C(C)C=C(C)C(O)C(OC)C(=O)C(C)CC(C)C=CC=CC=C1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 30
Group description: Low tacrolimus, everolimus, and steroids

Everolimus: Convert mycophenolate to everolimus with subsequent reduction in exposure to tacrolimus
Eligibility criteria:
Inclusion Criteria:

At least 18 years of age and able to give informed consent.
Received a first or repeat cadaveric (including ECD) or living donor renal transplant.
Patient has stable graft function, defined as no change of greater than 40% of baseline serum creatinine and no acute rejection during the past month.
Currently receiving tacrolimus, mycophenolate mofetil and prednisone as their immunosuppression regimen

Exclusion Criteria:

Biopsy proven acute rejection episode that occurred within the past month.
Malignancy within the past 3 years, except for non-melanoma skin cancer.
Currently enrolled in an investigational drug trial.
Woman of child bearing potential not utilizing an effective form of birth control.
Patients with uncontrolled dyslipidemia, defined at serum fasting LDL >200 mg/dL or serum fasting triglycerides >500 mg/dL.
Patients with a spot urine protein to creatinine ratio of > 800 mg of protein per gram of creatinine.
WBC < 2,000 cells/mm3
Platelets < 75,000 cells/mm3
Patients who have received an organ transplant other than a kidney.
Patients with a history of biopsy proven FSGS, MPGN, or PGN.
Intervention: Lansoprazole
Trial phase: Phase 1
ATC code: A02BC03 | A02BC06 | A02BC53 | A02BD02 | A02BD03 | A02BD07 | A02BD09 | A02BD10
SMILES: Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 8
Group description: Single oral dose of 30 mg dexlansoprazole delayed-release orally disintegrating tablet
Eligibility criteria:
Inclusion Criteria:

The male or female sensory panelist is between 25 and 80 years of age (inclusive), healthy volunteers for study participation, and is able to read, understand, and sign and date a written informed consent form (ICF) and any required privacy authorization before study participation.
In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
The sensory panelist is qualified based on documented training and experience: All panelists will be provided by Senopsys, LLC: Panelists have been trained to detect, identify, recognize, and accurately describe different taste elements and flavor combinations and to measure oral disintegration times. Training is initially accomplished by tasting model compounds and learning to recognize and describe these accurately. These abilities are then honed and refined through additional experience in performing product testing.

Exclusion Criteria:

Has a history of any illness that, in the opinion of the investigator or the sensory panelist's general practitioner, might confound the results of the study or pose an additional risk in administering study drug(s) to the sensory panelist. This may include but is not limited to: a history of relevant drug or food allergies; history of cardiovascular or central nervous system disease; history or presence of clinically significant pathology; recent history of disease involving head, neck, esophagus (especially malignancy, radiation therapy, fungal infection where taste perception can be altered) or history of mental disease.
If female, the sensory panelist is pregnant, nursing, planning to become pregnant during the study.
Has a known hypersensitivity to dexlansoprazole or any component of dexlansoprazole delayed-release orally disintegrating (OD) tablet or proton pump inhibitor (PPI) (including lansoprazole, omeprazole, rabeprazole, pantoprazole, or esomeprazole).

Is currently taking any contraindicated medications.

-
Intervention: Dapagliflozin
Trial phase: Phase 3
ATC code: A10BD15 | A10BD21 | A10BD25 | A10BK01
SMILES: CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 139
Group description: Dapagliflozin 10 mg oral Tablet once daily for 24 weeks + Background Insulin
Eligibility criteria:
Inclusion Criteria:

Subjects must have type 2 diabetes with inadequate glycemic control, defined as HbA1c ≥ 7.5% and ≤ 11.0% obtained at screening visit
Subjects must be taking a stable mean dose of ≥ 20 IU injectable insulin daily for at least 8 weeks prior to enrollment

Inclusion criteria for randomization:

HbA1c ≥ 7.5 and ≤ 10.5% at Day -14

Exclusion Criteria:

Treatment with more than two oral antidiabetic (OAD) agents within 6 weeks of Enrollment
History of diabetic ketoacidosis of hyperosmolar nonketotic coma
Clinically diagnosed Type 1 diabetes mellitus
Congestive heart failure defined as New York Heart Association (NYHA) stage III and IV
Severe uncontrolled hypertension defined as systolic blood pressure (SBP) ≥ 180 mmHg and/or diastolic blood pressure (DBP) ≥ 110 mmHg
History of unstable or rapidly progressing renal disease
History of severe hepatobiliary disease
Mallingancy within 5 years of the screening/enrollment visit
Intervention: Midazolam
Trial phase: Phase 3
ATC code: N05CD08
SMILES: Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 38
Group description: midazolam was given at 0.5mg/kg, pre-operatively single dose
Eligibility criteria:
Inclusion Criteria:

Pediatric patients ages 2-9 years
ASA class I-II
inpatient surgeries of at least 2 hours duration
requiring postoperative admission of at least 23 hours Exclusion Criteria:

Exclusion Criteria:

contraindication to preoperative sedation, known allergy or sensitivity to the study medications,
those who lack legal representative consent
Patients with weights lying below the 5th percentile or above the 95th percentile according to the current published CDC growth chart will also be excluded regardless of existing specific contraindication.
Intervention: Zolpidem
Trial phase: Phase 3
ATC code: N05CF02
SMILES: Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 42
Group description: zolpidem was given orally 0.25mg/kg pre-operatively single dose
Eligibility criteria:
Inclusion Criteria:

Pediatric patients ages 2-9 years
ASA class I-II
inpatient surgeries of at least 2 hours duration
requiring postoperative admission of at least 23 hours Exclusion Criteria:

Exclusion Criteria:

contraindication to preoperative sedation, known allergy or sensitivity to the study medications,
those who lack legal representative consent
Patients with weights lying below the 5th percentile or above the 95th percentile according to the current published CDC growth chart will also be excluded regardless of existing specific contraindication.
Intervention: Raltegravir
Trial phase: Phase 2
ATC code: J05AJ01 | J05AR16 | J05AX08
SMILES: Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 11
Group description: Patients will be offered to switch their protease inhibitor containing regimen to a raltegravir (400mg twice daily, orally) based regimen while maintaining the same background therapy.

Raltegravir
Eligibility criteria:
Inclusion Criteria:

Documented HIV-1 infection in female patients, age ≥18 years
Patients receiving antiretroviral therapy consisting of at least 2 antiretroviral agents other than protease inhibitor plus a ritonavir-boosted protease inhibitor (PI) for at least the previous 6 months
Plasma HIV viral load <50 copies/ml on current boosted PI containing regimen for ≥ 6 months prior to study entry
Fasting LDL cholesterol >130 mg/dl
Fasting triglycerides <450 mg/dl

Exclusion Criteria:

History of virological failure during previous antiretroviral therapy
Intervention: Melphalan
Trial phase: Phase 1
ATC code: L01AA03
SMILES: N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 14
Group description: Patients receive melphalan intra-arterial (IA) on day 1. Treatment repeats every 28 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.

Melphalan: Given IA
Eligibility criteria:
Inclusion Criteria:

Newly diagnosed patients with unilateral group D retinoblastoma
Magnetic resonance imaging (MRI) (or computed tomography [CT] if MRI is not available) of the brain must be performed within 14 days prior to study entry
Diagnostic examination under anesthesia (EUA) must be performed within 14 days prior to study entry
Rapid central review confirmation of group D disease based on RetCam images from diagnostic EUA must be obtained before starting treatment
Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2
Patients must have a life expectancy of >= 8 weeks

Patients must have adequate renal function, defined as:

Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 or

A serum creatinine based on age/gender as follows:

1 month to < 6 months: 0.4 mg/dL
6 months to < 1 year: 0.5 mg/dL
1 to < 2 years: 0.6 mg/dL
2 to < 6 years: 0.8 mg/dL
6 to < 10 years: 1 mg/dL
10 to < 13 years: 1.2 mg/dL
13 to < 16 years: 1.5 mg/dL (male); 1.4 mg/dL (female)
>= 16 years: 1.7 mg/dL (male); 1.4 mg/dL (female)
Total bilirubin =< 1.5 x upper limit of normal (ULN) for age
Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) < 2.5 x upper limit of normal (ULN) for age

Exclusion Criteria:

Patients with bilateral disease
Unilateral retinoblastoma with group A, B, C, or E eyes
Prior chemotherapy or radiation therapy for this disease (laser and cryotherapy are allowed and are not considered exclusion criteria)
Clinical or neuroimaging evidence of extraocular disease or orbital optic nerve involvement
Intervention: Methacholine Chloride
Trial phase: Phase 3
SMILES: CC(=O)OC(C)C[N+](C)(C)C.[Cl-]
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 10
Group description: children with bronchial asthma

Methacholine Chloride (SK-1211)
Eligibility criteria:
Inclusion Criteria:

Diagnosis of bronchial asthma
FEV1/FVC must be 70% or more
<10% decrease in FEV1 in response to inhalation of normal saline

Exclusion Criteria:

Moderate or severe airflow limitation（FEV1<60% predicted）
Heart attack or stroke in last 3 months
Uncontrolled hypertension, systolic BP>200, or diastolic BP>100
known aortic aneurysm
Intervention: TEDUGLUTIDE
Trial phase: Phase 4
ATC code: A16AX08
SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CC(=O)O)C(=O)O)[C@@H](C)O)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)CC
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 8
Group description: Teduglutide 0.05 mg/kg/d administered subcutaneously for 7 days in either first intervention period or second intervention period
Eligibility criteria:
Inclusion criteria:

Short bowel syndrome
Dependent on parenteral nutrition

Exclusion criteria:

Pregnant, trying to become pregnant or lactating
Diabetes
Alcohol or drug abuse within the last year by history
Active Crohn's disease as evaluated by standard procedures employed by the investigator
History of radiation enteritis, scleroderma, celiac disease, tropical sprue, diabetes, chronic pseudo-obstruction or malignancies
Previous use of Teduglutide or potential allergies to Teduglutide or its constituents
Any hospitalization within 1 month before screening
Use of Octreotide, intravenous glutamine growth hormone or growth factors such as native Glucagon-like Peptide 2 (GLP-2) within the last 12 weeks

Infliximab or other biological agents, Azathioprine, Methotrexate, Cyclosporine, Tacrolimus, Sirolimus, should be stable for at least 8 weeks prior to baseline and remain stable during the study

- Any investigational drug within last 30 days

Diuretics and oral rehydration solutions will be required to be stable for ≥4 weeks prior to baseline evaluations and remain stable during the study
Change in dose of antimotility or secretory agents from 2 days prior to, and throughout the two phases and washout periods of the study
Use of tobacco products within the prior 1 month (since nicotine can affect permeability)
Use of NSAIDS or aspirin within the past week
Use of oral corticosteroids within the previous 6 weeks
Ingestion of artificial sweeteners such as Splenda (sucralose), Nutrasweet (aspartame), lactulose or mannitol 2 days each of the study measurement days, e.g., foods to be avoided are sugarless gums or mints and diet soda
History of pancreatitis
Primary renal impairment (estimated glomerular filtration rate (eGFR)) <30 ml/min.